前列腺癌免疫疗法。
Prostate cancer immunotherapy.
机构信息
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
出版信息
Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.
Abstract
The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.
摘要
免疫系统与前列腺癌之间的相互作用是几十年来研究的热点领域。最近，美国食品和药物管理局批准了两种首创的概念验证免疫疗法（sipuleucel-T 和 ipilimumab），这激发了人们更广泛地利用免疫来对抗癌症的兴趣。在前列腺癌的背景下，最受关注的免疫治疗策略是治疗性疫苗策略，以 sipuleucel-T 和 PROSTVAC-VF 为代表，以及 CTLA-4 和 PD-1 的免疫检查点阻断。更好地了解这些策略产生的免疫反应，并开发用于患者选择的预测性生物标志物，将指导这些治疗方法的合理联合，并为未来的免疫疗法提供基础。
相似文献
1
Prostate cancer immunotherapy.前列腺癌免疫疗法。
Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.
2
[Immunotherapy: a therapeutic revolution against prostate cancer?].[免疫疗法：对抗前列腺癌的治疗革命？]
Rev Med Suisse. 2013 May 22;9(387):1070-5.
3
Molecular insights into the development of T cell-based immunotherapy for prostate cancer.前列腺癌基于T细胞免疫疗法发展的分子见解
Expert Rev Clin Immunol. 2014 Nov;10(11):1547-57. doi: 10.1586/1744666X.2014.962515. Epub 2014 Sep 26.
4
Current status of immunological approaches for the treatment of prostate cancer.前列腺癌免疫治疗的研究现状。
Curr Opin Urol. 2012 May;22(3):197-202. doi: 10.1097/MOU.0b013e3283519ad5.
5
The evolving role of immunotherapy in prostate cancer.免疫疗法在前列腺癌中的不断演变的角色。
Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259.
6
Beyond sipuleucel-T: immune approaches to treating prostate cancer.除了西妥昔单抗-T：治疗前列腺癌的免疫疗法
Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z.
7
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.先前存在的免疫状态与转移性去势抵抗性前列腺癌患者接受 sipuleucel-T 和 ipilimumab 联合治疗的反应相关。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2020-002254.
8
Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.前列腺癌的免疫治疗和治疗性疫苗：当前策略及临床意义的更新。
Asian J Androl. 2014 May-Jun;16(3):364-71. doi: 10.4103/1008-682X.122585.
9
Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.将主动免疫疗法与免疫检查点阻断相结合用于晚期前列腺癌的治疗。
Asian J Androl. 2012 Jul;14(4):520-1. doi: 10.1038/aja.2012.45. Epub 2012 May 14.
10
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.T 细胞分析显示，CD4+CTLA-4+T 细胞频率高是前列腺癌 GVAX/ipilimumab 治疗后生存的主要预测因素。
Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.
引用本文的文献
1
Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.增强免疫反应——联合局部免疫疗法治疗前列腺癌。
Cells. 2022 Sep 7;11(18):2793. doi: 10.3390/cells11182793.
2
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.转移性激素敏感前列腺癌系统治疗的未来方向。
World J Urol. 2023 Aug;41(8):2021-2031. doi: 10.1007/s00345-022-04135-8. Epub 2022 Aug 27.
3
Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer.髓源性抑制细胞作为前列腺癌的关键参与者和有前景的治疗靶点
Front Oncol. 2022 Jul 4;12:862416. doi: 10.3389/fonc.2022.862416. eCollection 2022.
4
Synthesis of precision antibody conjugates using proximity-induced chemistry.利用邻近诱导化学合成精准抗体偶联物。
Theranostics. 2021 Aug 27;11(18):9107-9117. doi: 10.7150/thno.62444. eCollection 2021.
5
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance.乙二醛酶-1依赖性甲基乙二醛消耗维持转移性前列腺癌细胞中PD-L1的表达：癌症免疫监视逃逸的新机制及克服PD-L1阻断抗性的潜在新靶点。
Cancers (Basel). 2021 Jun 13;13(12):2965. doi: 10.3390/cancers13122965.
6
Loss of testosterone impairs anti-tumor neutrophil function.睾酮缺失会损害抗肿瘤中性粒细胞功能。
Nat Commun. 2020 Mar 31;11(1):1613. doi: 10.1038/s41467-020-15397-4.
7
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T.拼拼凑凑：为 sipuleucel-T 完成作用机制拼图。
J Natl Cancer Inst. 2020 Jun 1;112(6):562-573. doi: 10.1093/jnci/djaa021.
8
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.实体瘤和B细胞恶性肿瘤中的免疫检查点阻断，特别考虑CD200的作用。
Cancer Manag Res. 2017 Nov 13;9:601-609. doi: 10.2147/CMAR.S147326. eCollection 2017.
9
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.基于人表皮生长因子受体1（HER1）的疫苗在前列腺去势抵抗性癌患者中的安全性和免疫原性：剂量递增I期研究试验
Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. eCollection 2017.
10
Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?共刺激CD28/CTLA-4通路的遗传背景是前列腺癌的危险因素吗？
Pathol Oncol Res. 2017 Oct;23(4):837-843. doi: 10.1007/s12253-016-0180-4. Epub 2017 Jan 18.
本文引用的文献
1
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.在五个 NCI 前列腺癌室内试验中确定的肿瘤退缩和生长速度：生长速度常数作为治疗效果的指标。
Clin Cancer Res. 2011 Feb 15;17(4):907-17. doi: 10.1158/1078-0432.CCR-10-1762. Epub 2010 Nov 24.
2
Improved endpoints for cancer immunotherapy trials.癌症免疫疗法试验的改善终点。
J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8.
3
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
4
Prostate cancer as a model for tumour immunotherapy.前列腺癌作为肿瘤免疫治疗的模型。
Nat Rev Immunol. 2010 Aug;10(8):580-93. doi: 10.1038/nri2817.
5
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
6
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.抗程序性死亡-1 单药（MDX-1106）治疗难治性实体瘤的 I 期研究：安全性、临床活性、药效学和免疫相关性。
J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
7
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.基于痘病毒的 PSA 靶向免疫治疗转移性去势抵抗性前列腺癌的 II 期随机对照试验的总生存分析。
J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.
8
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.实体瘤免疫治疗疗效评价指南：免疫相关反应标准。
Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.
9
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.采用痘病毒 PSA 疫苗治疗转移性去势抵抗性前列腺癌的总生存相关免疫和预后因素。
Cancer Immunol Immunother. 2010 May;59(5):663-74. doi: 10.1007/s00262-009-0782-8. Epub 2009 Nov 5.
10
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.前沿：浸润前列腺肿瘤的肿瘤特异性CD8 + T细胞被诱导成为抑制细胞。
J Immunol. 2009 Oct 15;183(8):4848-52. doi: 10.4049/jimmunol.0900848.
Zotero 插件